Supporting the critical role of the PI3K-AKT pathway in ccRCC and the emerging notion as a promising druggable target, a recent study demonstrated a connection between targeted PI3Kβ inhibition with the small-molecule inhibitor TGX221 and loss of SETD2 [27]. This evidence concerns the gene PIK3CD and nonpapillary renal cell carcinoma.